Evidence map›Paper›PMID 14973552›Full record

ArticleOncogene2004

Gene expression profiling of ErbB receptor and ligand-dependent transcription.

Dhara N Amin, Archibald S Perkins, David F Stern

Abstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Dhara N AminDepartment of Molecular, Cellular and Developmental Biology, Yale University, New Haven, CT 06510, USA.
Archibald S Perkins
David F Stern
Yale University · US

Funding

SIGNALING BY NEUREGULINS AND ERBB4 IN BREAST CANCERR01CA080065 · NCI · YALE UNIVERSITY · PI STERN, DAVID F · 1999 to 2013
$4.4M
NCI NIH HHS R01CA80065
6 · The paper itself

Abstract

Overexpression of ErbB2 and ErbB4 receptors in breast cancers may be accompanied by contrasting clinical outcomes. To investigate the molecular mechanisms contributing to these differences, we undertook a comparative study of gene expression regulated by the two receptors. Agonistic antibodies were employed to activate ErbB2 and ErbB4 in isolation from the other ErbBs in breast cancer cells. Gene expression profiling using a 16 755-gene oligonucleotide array was performed to identify transcriptional targets of receptor activation. Our results indicate that, in the same cell line, ErbB2 and ErbB4 activation influence gene transcription differentially. Although there are genes that are regulated by signaling from both receptors, there are also receptor-specific targets that are preferentially regulated by each receptor. We further show that two ligands acting via the same receptor homodimer may activate different subsets of genes. Many of the induced genes are hitherto unidentified targets of ErbB signaling. These include ErbB4 targets EPS15R, GATA4, and RAB2 and ErbB2-activated HRY/HES1 and PPAP2A. Targets of ErbB2 homodimer signaling may be especially important as markers in breast cancer, where ErbB2 homodimerization mediated by overexpression and ligand-independent activation is common.

Indexed as

Breast NeoplasmsErb-b2 Receptor Tyrosine KinasesErbB ReceptorsFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansLigandsOligonucleotide Array Sequence AnalysisReceptor, ErbB-4Reverse Transcriptase Polymerase Chain ReactionTranscription, GeneticTumor Cells, CulturedUp-RegulationErb-b2 Receptor Tyrosine KinasesERBB4 protein, humanErbB ReceptorsLigandsReceptor, ErbB-4

Identifiers

PMID14973552
OpenAlexW2066764044

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.